Palisade Bio Statistics
Total Valuation
Palisade Bio has a market cap or net worth of $328.07 million. The enterprise value is $195.44 million.
| Market Cap | 328.07M |
| Enterprise Value | 195.44M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Palisade Bio has 173.58 million shares outstanding. The number of shares has increased by 4,310.71% in one year.
| Current Share Class | 173.58M |
| Shares Outstanding | 173.58M |
| Shares Change (YoY) | +4,310.71% |
| Shares Change (QoQ) | +1.99% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 67.17% |
| Float | 132.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.48 |
| P/TBV Ratio | 2.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.71
| Current Ratio | 23.71 |
| Quick Ratio | 23.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,649.40 |
Financial Efficiency
Return on equity (ROE) is -36.40% and return on invested capital (ROIC) is -24.95%.
| Return on Equity (ROE) | -36.40% |
| Return on Assets (ROA) | -23.40% |
| Return on Invested Capital (ROIC) | -24.95% |
| Return on Capital Employed (ROCE) | -20.75% |
| Weighted Average Cost of Capital (WACC) | 12.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +151.00% in the last 52 weeks. The beta is 1.51, so Palisade Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | +151.00% |
| 50-Day Moving Average | 1.92 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 47.26 |
| Average Volume (20 Days) | 4,821,618 |
Short Selling Information
The latest short interest is 31.52 million, so 18.16% of the outstanding shares have been sold short.
| Short Interest | 31.52M |
| Short Previous Month | 30.81M |
| Short % of Shares Out | 18.16% |
| Short % of Float | 23.75% |
| Short Ratio (days to cover) | 7.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.49M |
| Pretax Income | -24.15M |
| Net Income | -24.15M |
| EBITDA | -26.49M |
| EBIT | -26.49M |
| Earnings Per Share (EPS) | -$0.23 |
Balance Sheet
The company has $132.63 million in cash and n/a in debt, with a net cash position of $132.63 million or $0.76 per share.
| Cash & Cash Equivalents | 132.63M |
| Total Debt | n/a |
| Net Cash | 132.63M |
| Net Cash Per Share | $0.76 |
| Equity (Book Value) | 127.36M |
| Book Value Per Share | 0.76 |
| Working Capital | 127.62M |
Cash Flow
| Operating Cash Flow | -12.40M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2,750 |
| Net Borrowing | -311,000 |
| Free Cash Flow | -12.40M |
| FCF Per Share | -$0.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Palisade Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4,310.71% |
| Shareholder Yield | -4,310.71% |
| Earnings Yield | -7.36% |
| FCF Yield | -3.78% |
Analyst Forecast
The average price target for Palisade Bio is $10.50, which is 455.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.50 |
| Price Target Difference | 455.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 8, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Apr 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |